Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study. [electronic resource]
Producer: 20190722Description: e16065 p. digitalISSN:- 1536-5964
- Adult
- Aged
- Antineoplastic Agents -- adverse effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Disease Progression
- Docetaxel -- adverse effects
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Preliminary Data
- Prospective Studies
- Protein Kinase Inhibitors -- adverse effects
- Pyridines -- adverse effects
- Retreatment
- Survival Analysis
- Treatment Outcome
- Tubulin Modulators -- adverse effects
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.